Articles From: Harte Hanks Reports Third Quarter Results to Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc.


http://media.marketwire.com/attachments/201310/197741_HHlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1154976&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM --
Sign-up for Harte Hanks Reports Third Quarter Results investment picks
http://media.marketwire.com/attachments/201310/197741_HHlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1151337&ProfileId=051205&sourceType=1 BOSTON, MA --
Sign-up for Harte Hanks Wins Best in Big Data Award investment picks
Hartford Funds announced today that it has made enhancements to its defined contribution investment-only (DCIO) capabilities by strategically structuring and growing its team, including the appointment of Bill Dougherty, Senior Vice President at Hartford Funds, who will now oversee the firm’s DCIO distribution team of 10 individuals supporting the business.
Sign-up for Hartford Funds Enhances DCIO Market Capabilities investment picks
2014/11/18
For the second consecutive year, small businesses in greater Hartford are more likely to have hired in the past 12 months compared with peers nationally, according to The Hartford’s 2014 Small Business Success Study.
Sign-up for Hartford Hiring: For Second Consecutive Year, Local Small Business Owners Beat National Hiring Average investment picks
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea announced that it will no longer be providing its HART-Trachea product for future transplant procedures performed at Krasnodar, Russia as part of the ongoing airway transplant studies there.
Sign-up for Harvard Apparatus Regenerative Technology No Longer Supporting Studies in Russia; Will Continue Focus on Preclinical Processes in the U.S. and EU investment picks
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and nine months ended September 30, 2014.
Sign-up for Harvard Apparatus Regenerative Technology Reports Operating Results for the Third Quarter Ended September 30, 2014 investment picks
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its third quarter ended September 30, 2014 before market trading hours on Thursday, November 6, 2014.
Sign-up for Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2014 Financial Results and Investor Teleconference for November 6, 2014 investment picks
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has recently been informed by the principal investigator in the Russian regenerated trachea transplant studies in which it is taking part that one of the patients in that study has recently passed away.
Sign-up for Harvard Apparatus Regenerative Technology Updates Patient Status investment picks
Expected to Add $7.5 Million to $8.5 Million in Revenue in 2015 HOLLISTON, Mass., Oct.
Sign-up for Harvard Bioscience Acquires Multi Channel Systems MCS GmbH and Triangle BioSystems, Inc. investment picks
HOLLISTON, Mass., Nov.
Sign-up for Harvard Bioscience Appoints Bertrand Loy to Board of Directors investment picks
Operational Improvements Produce Increases in Operating Income and Margins HOLLISTON, Mass., Oct.
Sign-up for Harvard Bioscience Reports Third Quarter 2014 Results investment picks
2014/9/17
http://media.marketwire.com/attachments/201401/215925_11Varonis_Horizontal_HEX_Whitespace.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1145200&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Harvard Business Review Highlights 'The Danger From Within' as Varonis Continues to Protect Companies From Internal Threats investment picks
2014/10/14
LAS VEGAS , Oct.
Sign-up for Harvard Business Review Names Steve Wynn Among "The Best-Performing CEOs in the World" investment picks
Allergan, Inc.’s (NYSE: AGN) (the “Company”) Chairman of the Board and Chief Executive Officer, David E.I. Pyott, has been ranked the 4 th best-performing CEO in the world by the Harvard Business Review (HBR). Mr.
Sign-up for Harvard Business Review Ranks David Pyott One of the Top 5 CEOs in the World investment picks
DENVER , Oct.
Sign-up for Harvard Business Review Recognizes DaVita HealthCare Partners investment picks
Harvest Capital Credit Corporation (“Harvest Capital” or the “Company”) (NASDAQ: HCAP ) announced that its Board of Directors declared distributions of $0.1125 per share for the months of October, November and December.
Sign-up for Harvest Capital Credit Corporation Announces September 30, 2014 Financial Results and Declares Distributions for October, November and December investment picks
Harvest Capital Credit Corporation (NASDAQ: HCAP ), announced today that it will report financial results for the fiscal quarter ended September 30, 2014 before market open on Thursday, November 13, 2014.
Sign-up for Harvest Capital Credit Corporation to Report Third Quarter 2014 Results on November 13, 2014 investment picks
2007/12/13
Lock in your 2007 gains while keeping taxes low.
Sign-up for Harvest Gains in Your Portfolio investment picks
HOUSTON , Nov.
Sign-up for Harvest Natural Resources Announces 2014 Third Quarter Results investment picks
http://media.marketwire.com/attachments/201410/80058_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156789&ProfileId=051205&sourceType=1 ATLANTA, GA --
Sign-up for Harvest Soul Chewable Juices Gain GA Department of Agriculture Approval Allowing for Immediate Production investment picks
2014/12/4
Harvey Nash Inc. today announced the opening of a Harvey Nash executive search office in Boston.
Sign-up for Harvey Nash Executive Search Opens Boston Office investment picks
NEW YORK , Oct.
Sign-up for Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc. investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Harte Hanks Reports Third Quarter Results to Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent